Clinical trial
Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients…
NCT00353587 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00353587 |
|---|---|
| Title | Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin |
| Official title | Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes |
| Intervention type | Drug |
| Interventions | MBX-102, Placebo, Actos |
| Enrollment | 396 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Jul 18, 2006 |
| Last update posted | May 1, 2015 |
| Countries | Argentina, India, Israel, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: